EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Treatment strategy for systemic lupus erythematosus using belimumab as indicated by multi‐omics analysis

Keishi Fujio, Toshiyuki Ushijima, Tatsuki Abe, Tomohisa Okamura, Sang‐Cheol Bae, Yumi Tsuchida

Rheumatology & Autoimmunity · 2025-06 · 5 (2) · 81-87

DOI: 10.1002/rai2.70001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology & Autoimmunity, online erschienen am 12.03.2025. Verfasst von Keishi Fujio und 5 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Science and Technology Agency.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Belimumab is an antibody targeting the cytokine B‐cell activating factor (BAFF), which is crucial for B cell differentiation, and is the first molecularly targeted drug approved for systemic lupus erythematosus (SLE). The primary endpoints have been met in clinical trials of belimumab involving patients with active SLE without severe organ complications, as well as in trials involving patients with lupus nephritis. In addition, the effects of belimumab in preventing relapses and reducing glucocorticoid use have been confirmed. Moreover, there were no significant differences in the incidences of many adverse events between the belimumab and placebo groups. Recent multi‐omics analyses have revealed that the cells targeted by belimumab are limited to naïve B cells and a subset of memory B cells. These findings align with the efficacy and safety profile of belimumab. An improved understanding of the mechanism of action of belimumab could support its use earlier during the treatment course or in a broader range of SLE cases.

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Science and Technology Agency

Zitieren

APA

Fujio, K., Ushijima, T., Abe, T., Okamura, T., Bae, S., & Tsuchida, Y. (2025). Treatment strategy for systemic lupus erythematosus using belimumab as indicated by multi‐omics analysis. Rheumatology & Autoimmunity, 5(2), 81-87. https://doi.org/10.1002/rai2.70001

Vancouver

Fujio K, Ushijima T, Abe T, Okamura T, Bae S, Tsuchida Y. Treatment strategy for systemic lupus erythematosus using belimumab as indicated by multi‐omics analysis. Rheumatology & Autoimmunity. 2025;5(2):81-87. doi:10.1002/rai2.70001

BibTeX
@article{Fujio2025,
  author = {Fujio, Keishi and Ushijima, Toshiyuki and Abe, Tatsuki and Okamura, Tomohisa and Bae, Sang‐Cheol and Tsuchida, Yumi},
  title = {Treatment strategy for systemic lupus erythematosus using belimumab as indicated by multi‐omics analysis},
  journal = {Rheumatology & Autoimmunity},
  year = {2025},
  volume = {5},
  number = {2},
  pages = {81--87},
  doi = {10.1002/rai2.70001}
}
Kostenlos starten →